BCL2L1 and endometrium neoplasm: IHC staining results showed that compared with the control mice, onvansertib treatment significantly reduced the expression of Ki-67 by 44.01%, Plk1 expression by 40.6%, and Bcl-xL expression by 27.23%.in endometrial tumors (Figure 6B).